China Shineway Pharmaceutical Group saw the highest growth of 1.99% in patent filings in June and no patents were granted in April in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 0.03% and no change in grants. GlobalData’s DataBook provides a comprehensive analysis of China Shineway Pharmaceutical Group’s patent filings and grants. Buy the databook here.
China Shineway Pharmaceutical Group has been focused on protecting inventions in World Intellectual Property Organization(WIPO) with two publications in Q2 2024
The World Intellectual Property Organization(WIPO) Patent Office dominates the patent filings with nearly 50% of filings. The World Intellectual Property Organization(WIPO), European Patent Office(EPO), United States(US), and Spain(ES) patent Office are among the top ten patent offices where China Shineway Pharmaceutical Group is filings its patents. Among the top granted patent authorities, China Shineway Pharmaceutical Group has 100% of its grants in Spain(ES).
Dow and OMV could be the strongest competitors for China Shineway Pharmaceutical Group
Energy infrastructure related patents lead China Shineway Pharmaceutical Group portfolio
China Shineway Pharmaceutical Group has highest number of patents in energy infrastructure.
For comprehensive analysis of China Shineway Pharmaceutical Group's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.